Eisai has opened a new packaging facility at its Hatfield, Hertfordshire production plant in the UK, ahead of plans to launch new products.
The Hatfield production plant is operated by the company’s UK manufacturing subsidiary, Eisai Manufacturing.
UK Minister for Life Sciences George Freeman said: "Pharmaceuticals manufacturing is important to our economy.
"Eisai’s investment in this new facility will help grow pharmaceutical export and is another vote of confidence for the UK’s world-class life sciences sector."
The plant serves as a global supply center for new products such as antiepileptic agent Fycompa while also functioning as a production and packaging base for countries in Europe.
Housing a packaging line with cutting-edge technology, the new facility covers a total floor space of around 2,900m², representing an increase in size of about 40%.
The facility is designed to cope with highly potent compounds to handle the packaging of the company’s investigational anticancer agent lenvatinib (generic name).
Eisai CEO Haruo Naito said: "Since the establishment of the Eisai London Research Laboratories in 1990, for over nearly 25 years we have continued to invest in the UK as our base in Europe.
"I am proud to announce that the opening of this new high tech facility will enable the supply of innovative new medicines, such as anticancer agents lenvatinib and Halaven as well as antiepileptic agent Fycompa, from our plant here in Hatfield to contribute to patients all over the world."